Hao Derek Cheng

Hao Derek Cheng has worked at Yurogen Biosystems LLC since 2022 as the Chief Scientific Officer. Prior to that, they worked at Entrada Therapeutics as a Project Lead from 2020. From 2018 to 2020, they were a Scientist at Occulo Bio LLC (Insmed Incorporated), where they drove two therapeutic enzyme drug discovery programs, established a human PBMC assay platform, developed and characterized antigen-specific T cells, and maintained collaborative partnerships with external academic research groups and CROs. From 2017 to 2018, they were a Visiting Student at Walter Reed Army Institute of Research. From 2012 to 2016, they were a Graduate Student at Dartmouth College, where they identified signatures of antibody neutralization breadth at HIV-1 CD4bs, expressed gp120 library on yeast cell surface and characterized HIV mAbs and polyclonal serum, identified three amino acid mutations critical for neutralization through machine learning methods, and constructed novel gp120 probes and performed single B cell sorting and antibody cloning. In 2016, they were a Visiting Student at Fred Hutchinson Cancer Research Center Research, where they evaluated high-dimensional immune responses data collected from rhesus macaque SHIV vaccine study and built predictive models of vaccine induced immune responses using machine learning. Prior to that, they were a Research Assistant at Tsinghua University from 2011.

Hao Derek Cheng is currently a PhD Candidate at Dartmouth College in the field of Microbiology and Immunology. Prior to this, they obtained a Bachelor of Science (B.S.) from Wuhan University in the field of Life Sciences.